CTKB
Cytek Biosciences, Inc.NASDAQHealthcare$4.53+1.12%ClosedMarket Cap: $582.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.70
P/S
2.88
EV/EBITDA
-32.82
DCF Value
$0.76
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.8%
Operating Margin
-20.0%
Net Margin
-33.0%
ROE
-18.0%
ROA
-14.4%
ROIC
-10.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $62.1M | 52.9% | $-5.6M | $-44.1M | $-0.34 | — |
| FY 2025 | $201.5M | 51.8% | $-40.4M | $-66.5M | $-0.52 | — |
| Q3 2025 | $52.3M | 52.7% | $-9.2M | $-5.5M | $-0.04 | — |
| Q2 2025 | $45.6M | 52.3% | $-10.6M | $-5.6M | $-0.04 | — |
| Q1 2025 | $41.5M | 48.6% | $-15.0M | $-11.4M | $-0.09 | — |
| Q4 2024 | $57.5M | 58.5% | $3.0M | $9.6M | $0.07 | — |
| FY 2024 | $200.5M | 55.4% | $-20.5M | $-6.0M | $-0.05 | — |
| Q3 2024 | $51.5M | 56.3% | $-4.2M | $941.0K | $0.01 | — |
| Q2 2024 | $46.6M | 54.6% | $-8.5M | $-10.4M | $-0.08 | — |
| Q1 2024 | $44.9M | 51.3% | $-10.7M | $-6.2M | $-0.05 | — |
| Q4 2023 | $58.2M | 56.8% | $-137.0K | $5.5M | $0.04 | — |
| FY 2023 | $193.0M | 56.7% | $-27.8M | $-12.1M | $-0.09 | — |